Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Necrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    422 result(s) found for: Necrosis. Displaying page 9 of 22.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2021-001534-19 Sponsor Protocol Number: APHP200015 Start Date*: 2021-05-21
    Sponsor Name:AP-HP/DRCI
    Full Title: Direct oral Anticoagulants for Prevention of lEft ventRIcular Thrombus after anterior acute myocardial InFarction
    Medical condition: Left ventricular (LV) thrombus after acute myocardial infarction (AMI)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001575-16 Sponsor Protocol Number: 2017-02-32-005 Start Date*: 2021-11-29
    Sponsor Name:Centre Régional de lutte contre le Cancer Eugène Marquis
    Full Title: A multicenter open-label randomized controlled prospective phase II study evaluating the efficacy of Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) combined with Capecitabine ...
    Medical condition: Patients having operable intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10073077 Intrahepatic cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001419-21 Sponsor Protocol Number: RC19_0042 Start Date*: 2019-09-16
    Sponsor Name:CHU de Nantes
    Full Title: Optimization of skin preparation to reduce Cutibacterium acnes colonization in superficial and deep samples during prosthetic shoulder surgery in male patients
    Medical condition: Cutibacterium acnes infection in shoulder arthroplasty with males
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005723-20 Sponsor Protocol Number: RC31/20/0445 Start Date*: 2022-02-10
    Sponsor Name:CHU de Toulouse
    Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease
    Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002313-18 Sponsor Protocol Number: PAMORA-AP_2020 Start Date*: 2020-12-22
    Sponsor Name:Mech-Sense, Aalborg University Hospital
    Full Title: The effects of opioid receptor antagonism on acute pancreatitis: An investigator initiated, randomized, placebo-controlled, double-blind clinical trial
    Medical condition: Acute pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10033647 Pancreatitis acute PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001302-25 Sponsor Protocol Number: 2008-0312-08 Start Date*: 2009-11-05
    Sponsor Name:Lab for pharmaceutical biology [...]
    1. Lab for pharmaceutical biology
    2. Department of Urology
    Full Title: Evaluation of the benefits and effects of hypericin Photodynamic therapy (PDT) in the clinical treatment of superficial bladder carcinoma.
    Medical condition: the study population consists of 10 patients with anatomopathologically proven muscle invasive TCC without metastasis. These patients require a cystoscopy. Before the planned cystoscopy, the bladde...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034942 Photodynamic therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003374-30 Sponsor Protocol Number: SONIC-ALA Start Date*: 2021-10-25
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: A pilot study to Evaluate the Safety and Feasibility of Sonodynamic Therapy Using the ExAblate MRI-Guided Focused Ultrasound in the Treatment of Cerebral Glioblastomas.
    Medical condition: IV degree lobar glioblastoma with a diameter of less than 5 cm.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003922-27 Sponsor Protocol Number: PAM-UMCG-002 Start Date*: 2024-02-08
    Sponsor Name:University Medical Center Groningen (UMCG)
    Full Title: Neo-adjuvant Pembrolizumab as alternative to radio(chemo)therapy in MMRd uterine cancer
    Medical condition: Primary uterine cancer characterized with dMMR
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004403-12 Sponsor Protocol Number: APHP190871 Start Date*: 2020-10-26
    Sponsor Name:ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
    Full Title: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study
    Medical condition: The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004319-37 Sponsor Protocol Number: 001.4 Start Date*: 2019-06-19
    Sponsor Name:Medical University of Vienna, Department of Surgery
    Full Title: A prospective, randomised, single-blind explorative study to investigate the efficacy and safety of fat graft enrichment with autologous platelet lysate in female breast augmentation
    Medical condition: Fat grafting e.g. to the breast to restore small tissue defects is a very common and safe surgical procedure. Its main success among other is depended on the survival rate of the transferred fat ti...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10016251 Fat tissue increased PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003244-79 Sponsor Protocol Number: 20603 Start Date*: 2020-02-03
    Sponsor Name:Bayer AG
    Full Title: Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial in...
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10064939 Cardiovascular event prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) NL (Completed) DE (Completed) AT (Completed) ES (Completed) SE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003623-20 Sponsor Protocol Number: JCA-RIT-2007-01 Start Date*: 2008-03-12
    Sponsor Name:Dr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona
    Full Title: Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR). Study o...
    Medical condition: Se estudiaran los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002445-36 Sponsor Protocol Number: 0001 Start Date*: 2011-10-31
    Sponsor Name:Department of Clinical Oncology, Leiden University Medical Center
    Full Title: Neo-adjuvant dovitinib in patients with hepatocellular carcinoma prior to local treatment: a phase II study
    Medical condition: Hepatocellular carcinoma, not metastatic
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002442-23 Sponsor Protocol Number: GS-US-428-4025 Start Date*: 2017-01-09
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis
    Medical condition: Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020738-24 Sponsor Protocol Number: Version 1.2 (20/06/2011) Start Date*: 2010-10-12
    Sponsor Name:King's College London
    Full Title: Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA)
    Medical condition: Patients with established Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001190-28 Sponsor Protocol Number: KCL (Rheum) TACIT Version 2.1 Start Date*: 2007-05-09
    Sponsor Name:King's College London
    Full Title: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006644-19 Sponsor Protocol Number: CRISTAL Start Date*: 2009-01-29
    Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
    Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005532-18 Sponsor Protocol Number: PLX-CLI-03 Start Date*: 2017-01-02
    Sponsor Name:Pluristem Ltd.
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatmen...
    Medical condition: Critical Limb Ischemia (CLI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001960-31 Sponsor Protocol Number: S54348 Start Date*: 2013-05-03
    Sponsor Name:UZ Leuven
    Full Title: Combined drug Approach to Prevent Ischemia-reperfusion injury during Transplantation of Livers (CAPITL): a first-in-men study
    Medical condition: Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021018-49 Sponsor Protocol Number: FOILED Start Date*: 2012-05-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: Fish OIL optimal dosE Determination Study
    Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040070 Septic shock PT
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 17:51:23 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA